Clinical trials: Chemotherapy Induced Thrombocytopenia
Non-small Cell Lung Cancer
An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC
The purpose of this study is to explore the safety and efficacy of herombopag olamine tablets for thrombocytopenia induced by chemotherapy combined with immunotherapy in non-small cell lung cancer
- Trial name
- NCT05252091
- Testing
- herombopag olamine tablets
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Thrombocytopaenia
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or…
- Trial name
- NCT01147809
- Testing
- Eltrombopag olamine
- Where
- 86 sites in United States, Belgium and 11 more
- Volunteers
- 130 people
- Sponsor
- GlaxoSmithKline
Lung Cancer, Chemotherapy-Induced Thrombocytopenia
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung…
- Conditions
- Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer
- Trial name
- NCT00413283
- Testing
- Romiplostim, Gemcitabine, Carboplatin
- Where
- 113 sites in United States, Austria and 6 more
- Volunteers
- 63 people
- Sponsor
- Amgen
Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia
Single Arm Romiplostim to Prevent CIT
The goal of this clinical trial is to to assess the efficacy of romiplostim as a supportive care measure in patients with a new diagnosis of Ewing sarcoma receiving interval-compressed chemotherapy.
- Trial name
- NCT07048249
- Testing
- Romiplostim (AMG-531)
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Hematological Patients, Bleeding
Administration of Fibrinogen Concentrate for Refractory Bleeding
Platelet transfusions are widely employed to prevent or treat bleeding episodes in patients with thrombocytopenia. Patients with bone marrow failure secondary to haematological malignancy and chemotherapy frequently receive…
- Conditions
- Hematological Patients, Bleeding, Platelet Refractoriness
- Trial name
- FORMAT (NCT05091684)
- Testing
- Fibrinogen Concentrate Human
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia.
- Conditions
- Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
- Trial name
- NCT01933035
- Testing
- Immune Thrombocytopenics, Hypo-proliferative thrombocytopenics, Control Population
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Beth Israel Medical Center
Chemotherapy-induced Thrombocytopenia
The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies
Chemotherapy is an important treatment strategy for gynecological malignancies, such as ovarian cancer, advanced endometrial cancer, cervical cancer.
- Trial name
- NCT06099925
- Testing
- Hetrombopag
- Volunteers
- 48 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gastrointestinal Cancer, Gastrointestinal Neoplasms
Avatrombopag vs. Placebo for CIT in GI Malignancies
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
- Trial name
- ACT-GI (NCT05772546)
- Testing
- Avatrombopag
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Hanny Al-Samkari, MD
Thrombocytopenia
Thrombocytopenia Induced by Chemotherapy
Single blind, randomized, multicentric placebo controlled study to evaluate the efficacy of Study product in patient with Chemotherapy induced thrombocytopenia.
- Trial name
- papayaleaf (NCT03567798)
- Testing
- UPLAT
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Socrates School Of Health
Chemotherapy-Induced Thrombocytopenia
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
The study is aimed to evaluate the efficacy of different doses of hetrombopag compared to placebo, measured by the proportion of subjects that can complete two planned consecutive chemotherapy cycles with no modification of…
- Trial name
- NCT05261646
- Testing
- Hetrombopag
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chemotherapy Induced Thrombocytopenia
Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients
Chemotherapy Induced Thrombocytopenia is a common side-effect of bone marrow suppression as a result of a chemotherapy treatment.
- Trial name
- NCT00926354
- Testing
- AS101
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- BioMAS Ltd
Non-Hodgkin Lymphoma
Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
This is a monocentric, prospective phase II trial addressing safety and capability to prevent grade-4 Chemotherapy-induced Thrombocytopenia (CIT) of romiplostim in patients with NHL.
- Trial name
- ProRom (NCT01516619)
- Testing
- Romiplostim
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Andres J. M. Ferreri
Chemotherapy-Induced Thrombocytopenia
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Hetrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of solid tumors.
- Trial name
- NCT03976882
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of lymphomas measured by the ability to administer on-time, full-dose chemotherapy.
- Trial name
- NCT03343847
- Testing
- Romiplostim
- Sponsor
- Amgen
Chemotherapy in Non-Small Cell Lung Cancer
Spleen Radiotherapy Decreases Severe CIT in Advanced NSCLC (SPLEENIR)
Chemotherapy is one of the main treatments for advanced NSCLC. However, chemotherapy induced thrombocytopenia (CIT) is one of the most important limitations for subsequent chemotherapy of cancer.
- Trial name
- NCT02650700
- Testing
- spleen radiotherapy
- Volunteers
- 100 people
- Sponsor
- Xinqiao Hospital of Chongqing
Sarcoma, Soft Tissue, Osteosarcoma
Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
The purpose of this study is to study the effect of eltrombopag on chemotherapy induced thrombocytopenia. Thrombocytopenia is when there is a low number of platelets in the blood.
- Conditions
- Sarcoma, Soft Tissue, Osteosarcoma, Neoplasms, Connective and Soft Tissue
- Trial name
- NCT01491594
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
CTIT-Chemotherapy Induced Thrombocytopenia
TPO Combined With TPORA for Solid Tumors Effectiveness of cTit Above Degree II
This study was an open-label, controlled, single-center, prospective phase II trial. In this prospective, real-world study, consecutive patients meeting eligibility criteria will be enrolled and allocated to: Group A (Grade Ⅱ…
- Trial name
- NCT06769685
- Testing
- rhTPO, hypertrombopa
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinhua Central Hospital
Thrombocytopaenia
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy
SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 versus placebo as treatment for patients with…
- Trial name
- NCT00102726
- Testing
- SB497115
- Where
- 95 sites in United States, Argentina and 17 more
- Volunteers
- 183 people
- Sponsor
- GlaxoSmithKline
Chemotherapy-induced Thrombocytopenia
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung…
- Trial name
- NCT03471078
- Testing
- Avatrombopag
- Where
- 55 sites in United States, China and 5 more
- Volunteers
- 122 people
- Sponsor
- Sobi, Inc.
Chemotherapy-Induced Thrombocytopenia
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.
- Trial name
- NCT05864014
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 213 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.